Showing 1 - 10 of 148,413
counter- vailing effects, we exploit a policy reform in Norway with a gradual implementation of reference pricing across …
Persistent link: https://www.econbiz.de/10013285854
counter- vailing effects, we exploit a policy reform in Norway with a gradual implementation of reference pricing across …
Persistent link: https://www.econbiz.de/10014080046
a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub …-savings, and that patients' copayments decrease despite the extra surcharges under RP. -- pharmaceuticals ; regulation ; generic …
Persistent link: https://www.econbiz.de/10008749029
a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub …
Persistent link: https://www.econbiz.de/10013316129
This paper examines competition between generic and brand-name drugs in the regulated Spanish pharmaceutical market. A nested logit demand model is specified for the three most consumed therapeutic subgroups in Spain: statins (anticholesterol), selective serotonin reuptake inhibitors...
Persistent link: https://www.econbiz.de/10013124302
generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …. -- pharmaceuticals ; pharmacies ; generic substitution …
Persistent link: https://www.econbiz.de/10009691207
We study the impact of product margins on pharmacies' incentive to promote generics instead of brand-names. First, we construct a theoretical model where pharmacies can persuade patients with a brand-name prescription to purchase a generic version instead. We show that pharmacies' substitution...
Persistent link: https://www.econbiz.de/10013139185
generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …
Persistent link: https://www.econbiz.de/10013088216
experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products …
Persistent link: https://www.econbiz.de/10014198115
This paper studies the effect of two regulatory instruments - a price cap and a reference price system - a mandatory substitution rule, and the combination of both on generic competition in a Salop-type model with an off-patent brand-name drug and n differentiated generic versions. The price cap...
Persistent link: https://www.econbiz.de/10010510801